NewAmsterdam Pharma Company NV (NASDAQ: NAMS) is a late-stage biopharmaceutical company developing oral therapies for cardiometabolic diseases, specifically LDL-C lowering treatments for patients at cardiovascular risk. The company has no approved products and no significant product revenues as of the 10-K filed February 18, 2026. Its sole clinical program centers on obicetrapib, an oral, once-daily, selective CETP inhibitor being evaluated as an adjunct to statin therapy, both as a monotherapy and as a fixed-dose combination with ezetimibe. Two Phase 3 pivotal trials, BROADWAY (over 2,500 patients randomized) and BROOKLYN (over 350 patients randomized), met their primary LDL-C lowering endpoints with safety comparable to placebo, per results announced in December 2024 and July 2024, respectively. A cardiovascular outcomes trial, PREVAIL, is ongoing and targets a minimum follow-up period concluding no earlier than end of 2026. The company is incorporated in the Netherlands, relies entirely on third-party manufacturers, and has incurred net losses since inception.

Revenue model

No product revenue. The company is pre-commercial and funds operations through capital raises. No royalty, licensing, or product sales revenue is reported in the 10-K filed February 18, 2026.

Products and services

Obicetrapib: oral, once-daily, low-dose CETP inhibitor in late-stage clinical development for LDL-C lowering in ASCVD and heterozygous familial hypercholesterolemia (HeFH) patients. Fixed-dose combination of obicetrapib with ezetimibe also in development. Early-stage investigation of obicetrapib in Alzheimer's disease (Phase 2a, 13 patients, 24-week follow-up with initial data announced September 2023).

Customers and end markets

Target end market: patients with ASCVD or HeFH who have not reached LDL-C goals on existing lipid-lowering therapy, including statins. Company estimates approximately 30 million U.S. patients not at risk-based LDL-C goals despite treatment, including approximately 13 million with ASCVD. Prescribers are cardiologists and physicians treating cardiovascular risk. No commercial customers as of the filing date.

Value-chain role

Drug developer with no internal manufacturing. Relies entirely on third-party contract manufacturers for obicetrapib production and on third parties for clinical trial execution. Pre-commercial, with limited marketing and distribution experience.

Geographic exposure

Incorporated in the Netherlands. International operations noted with associated foreign exchange risk. Regulatory submissions targeted at both the FDA (United States) and EMA (European Union). No geographic revenue breakdown available given pre-revenue status.

Source: SEC 10-K, filed 2026-02-18

Industry: Pharmaceutical Preparations